Treatment of cancer using hypoxia activated prodrugs
AssigneeThreshold Pharmaceuticals, Inc.
InventorsJohn G. Curd, Stewart Kroll, Mark Matteucci, Charles P. Hart, Jian-Xin Duan
Life of this patent
Estimating the term…
Abstract
Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.
Claims18
A method of treating cancer comprising administering N,N′-bis(2-bromoethyl)phosphorodamidic acid (1-methyl-2-nitro-1H-imidazol-5-yl)methyl ester (TH-302) and a therapeutically effective dose of an anticancer drug that is not a hypoxia activated prodrug to a patient in need of cancer therapy,
- wherein TH-302 is administered intravenously in an amount in the range of 200 mg/m2 to 575 mg/m2 and administration of the anticancer drug that is not a hypoxia activated prodrug begins 30 minutes to 8 hours after administration of TH-302 is completed.
A pharmaceutical formulation comprising TH-302 as an active ingredient in an amount of about 50 mg/ml to about 300 mg/ml, a nonionic surfactant in an amount effective to act as a stabilizer, and ethanol as a carrier.
Dependencies are inferred from the claim text.